SS
VRCA icon

SBI Securities’s Verrica Pharmaceuticals VRCA Stock Holding History

SBI Securities’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Hold
0
– -$1 – 4323
2025
Q2 		– Hold
0
– – – 4136
2025
Q1 		– Sell
-1
Closed -$6 – 4102
2024
Q4 		$6 Buy
+1
New +$11 ﹤0.01% 3985

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

SBI Securities's VRCA Position: Q3 2025 in Review

SBI Securities held its Verrica Pharmaceuticals (VRCA) position steady in Q3 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4323.

SBI Securities first reported a position in VRCA in Q4 2024 and has held it in 1 quarter since. The position peaked at $6 in Q4 2024. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • SBI Securities held 0 shares of Verrica Pharmaceuticals worth $0 as of Q3 2025.
  • SBI Securities left its Verrica Pharmaceuticals share count unchanged in Q3 2025.
  • Verrica Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q3 2025, its #4323 holding.
  • SBI Securities first reported a position in Verrica Pharmaceuticals in Q4 2024 and has held it in 1 quarter since.
  • SBI Securities's Verrica Pharmaceuticals position peaked at $6 in Q4 2024.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.